{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-058902","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.493209+00:00","generated_at":"2026-06-23T07:32:54.504261+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Allarity Therapeutics appoints Jerry McLaughlin to Board of Directors, effective Oct 1, 2022","bullets":["Jerry McLaughlin appointed as Class II director, expanding board from six to seven members.","McLaughlin qualifies as independent director under NASDAQ rules; serves on Audit and Compensation Committees.","Compensation: $50k annual cash retainer, $7.5k Audit Committee fee, and options for 23k shares vesting over 36 months.","McLaughlin is CEO of Life Biosciences, former CEO of Neos Therapeutics and AgeneBio; 30 years biopharma experience.","Press release and updated company overview presentation furnished as Exhibits 99.1 and 99.2."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-058902","json":"https://secwatch.observer/filing/0001213900-22-058902.json","markdown":"https://secwatch.observer/filing/0001213900-22-058902.md","text":"https://secwatch.observer/filing/0001213900-22-058902.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022058902/0001213900-22-058902-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022058902/ea166296-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:32:54.504261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c2c9f7cddb","claim":"Jerry McLaughlin was appointed as director at Allarity Therapeutics, Inc..","evidence_excerpt":"To fill the vacancy, the Board appointed the following individual as a director of the Company, effective as of October 1, 2022: Class II Director : Jerry McLaughlin,","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022058902/0001213900-22-058902-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}